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CD45 is a membrane tyrosine phosphatase that modulates the function of the
hematopoietic cells. In vitro, agonist antibodies to CD45RO or CD45RB isoforms have
been shown to suppress microglial activation, but whether microglia in vivo express
these isoforms in HIV encephalitis (HIVE) is unknown. Brain sections from control and
HIVE were immunostained for CD45 isoforms using exon-speciﬁc antibodies (RA, RB,
RC and RO). RA and RC were limited to rare lymphocytes, while RB expression was
robust in microglia and inﬂammatory cells. RO was low in control microglia, but
increased in HIVE. RO was also localized to macrophages and CD8+ T cells. Targeting
CD45 in vivo with isoform-speciﬁc antibodies remains a therapeutic option for neuroin-
ﬂammatory diseases.
Brain Pathol 2006;16:256–265.
INTRODUCTION
The leukocyte common antigen (LCA:
CD45) is a prototype transmembrane pro-
tein tyrosine phosphatase (PTPase) and is
expressed in all nucleated hematopoietic
cells (54). The CD45 protein exists as mul-
tiple isoforms as a result of alternative splic-
ing of variable exons (4/A, 5/B and 6/C);
the largest isoform (ABC) includes all three
of these exons and the smallest isoform (O)
lacks all three exons. Five different isoforms
of CD45 (ABC, AB, BC, B and O) have
been identiﬁed on human leukocytes and
these can be recognized by antibodies spe-
ciﬁc to variable exons (A, B or C) or by
αCD45RO (45). Although the extracellular
domains differ among different isoforms,
all forms share identical transmembrane
and cytoplasmic domains including the
phosphatase domains (52, 54).
CD45 is one of the most abundantly
expressed molecules in lymphocytes (com-
prising approximately 10% of all surface
proteins) and is crucial in lymphocyte
development and antigen signaling (2, 12,
23, 54). Consequently, CD45 mutations
are associated with severe combined
immunodeﬁciency in mice and humans
(5, 28, 51). In lymphocytes, CD45 is
expressed in a cell subset-speciﬁc and
activation-dependent manner. For
instance, naïve T cells express a high
molecular weight isoform (RA+/RO−) but
upon activation switch to the smallest iso-
form (RA−/RO+) (16, 31). At the cellular
level, the CD45 phosphatase targets several
families of proteins, including the Src fam-
ily tyrosine kinases and Janus kinases (41),
resulting in positive or negative signaling
(2, 4, 54). In addition to lymphocytes,
recent studies demonstrate that CD45 can
modulate activation and proliferation of
several inﬂammatory cell types including
granulocytes, mast cells and monocyte-
lineage cells, broadening its role as a regu-
lator of inﬂammatory responses (8, 20, 35,
48, 57).
In  the central nervous system (CNS),
microglia constitute a distinct glial cell
population that is derived from hemato-
poietic cells in the bone marrow (17, 29,
42). As resident brain macrophages, micro-
glia function as sentries, but when activated
they can mediate tissue damage, a scenario
considered for several CNS inﬂammatory
disorders (10, 15, 27). In AIDS dementia
and HIV encephalitis (HIVE), microglia
and macrophages are productively infected
by HIV-1 and show diffuse inﬂammatory
activation, which ultimately leads to neu-
ronal damage and CNS dysfunction (7, 11,
14, 43). Microglia in normal human brain
express CD45 and increases in microglial
CD45 expression have been detected in
Alzheimer’s disease, graft-versus-host dis-
ease, multiple sclerosis, and in HIVE (1, 7,
24, 30, 33, 46). Furthermore, studies in
rodent and human cells suggest that CD45
can downregulate microglial activation.
For example, murine microglia devoid of
CD45 expression demonstrate an over-
activated phenotype (49, 50), while in
human microglia, an agonist antibody
(αCD45RO, clone UCHL-1) can stimu-
late CD45 tyrosine phosphatase activity
and suppress granulocyte-macrophage
colony-stimulating factor (GM-CSF) sig-
nal transduction and cell proliferation (48).
CD45 also downregulates HIV-1 replica-
tion in microglia, indicating that there
might be potential for targeting this phos-
phatase as a therapy for AIDS dementia
(25).
Despite these data indicating functional
importance of CD45 in microglia, the
CD45 isoform expression by microglia and
macrophages in HIV-1-infected human
brain is not known. Furthermore, the
identity of CD45 isoforms other than
CD45RO on CNS-inﬁltrating T cells is
unknown. We therefore sought to investi-
gate changes in CD45 isoform expression
in the human CNS as it pertains to HIVE
and also asked whether there is cell-type or
activation-dependent expression of CD45
isoforms.
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MATERIALS AND METHODS
Patient  material.  Parafﬁn-embedded,
formalin-ﬁxed brain tissues from 22 pa-
tients were obtained from the Manhattan
HIV-1 Brain Bank, National NeuroAIDS
Tissue Consortium (37). Information re-
garding the case history and other associ-
ated systemic illnesses has been previously
reported (6, 7, 58). Our patient material
was distributed into three groups: HIVE
(n =  9), HIV-seropositive without HIVE
(HIV+, n = 6) and HIV-seronegative indi-
viduals (HIV−, n = 8). The mean ages were
45.6 ± 3.5  (HIV−), 42.5  ± 2.7  (HIV+)
and 38.5 ± 2.5 (HIVE) and were not sig-
niﬁcantly different (P > 0.05). One HIVE
and two HIV+ patients received highly ac-
tive antiretroviral therapy (HAART). For
HIVE, one to two regions of the frontal
lobe, each demonstrating microglial nod-
ules and/or multinucleated giant cells
(MGCs), were selected for analysis. Con-
trol (non-HIVE) brain sections derived
from the corresponding regions of the
brain lacked focal pathology on hematox-
ylin and eosin. Because of the known dif-
ference between gray matter and white
matter microglia (10) and the variable rep-
resentation of the gray matter in each sec-
tion, cell counts from white matter only
were compared for analysis.
CD45, CD3 and CD8 immunohis-
tochemistry (IHC). Deparafﬁnized slides
were  boiled for epitope retrieval, treated
with 3% H2O2, blocked with normal goat
serum, and then incubated with primary
antibodies overnight at 4°C, as described
(7). The antibodies used in this study,
their dilutions and the methods of IHC
employed are listed in Table  1. Staining
with  αCD45 antibodies was completed
using the avidin–biotin complex method
with or without the tyramide signal ampli-
ﬁcation (TSA) system (NEN Life Science
Products, Boston, Mass.), as indicated.
Brieﬂy, biotin-labeled secondary methods
were  employed followed by exposure to
horseradish peroxidase (HRP)-labeled
streptavidin and then the TSA reagent as
indicated by the manufacturer’s instruc-
tions. As a negative control, sections were
incubated with normal mouse IgG1, 2a or
2b (BD Biosciences Pharmingen, San
Diego, Calif.). IHC for CD3, CD8 and
CD68 was performed as indicated in
Table 1 and as described (6, 7, 58). Parafﬁn
sections of human tonsils were used as pos-
itive controls. The speciﬁcity of the CD45
isoform antibodies was conﬁrmed addi-
tionally by Western blot analysis (25).
IHC  without  epitope  retrieval  or
TSA. CD45RB and CD45RO staining on
serial slides of a single parafﬁn block was
compared using three different IHC meth-
ods with increasing sensitivity: (i) without
antigen retrieval (AR); (ii) with AR; and
(iii) with AR and TSA. All other experi-
ments conducted with CD45 were per-
formed using the most sensitive technique,
that is, epitope retrieval plus TSA, unless
otherwise stated.
Double-label IHC. For double-label
IHC, and occasionally for single label
IHC, alkaline phosphatase-labeled anti-
mouse IgG was used as the secondary,
followed by 5-bromo-4-chloro-3-indolyl
phosphate/nitro blue tetrazolium (BCIP/
NBT) to develop color. For most double
labeling, staining was performed sequen-
tially. The ﬁrst primary antibody was
developed with an HRP-conjugated sec-
ondary antibody or biotin/streptavidin,
and diaminobenzidine (brown), followed
by the second primary antibody and then
the alkaline phosphatase-labeled secondary
and NBT (blue). In some instances, the
TSA system was utilized for both anti-
bodies, as outlined in Table 1. To ensure
speciﬁcity and sensitivity of the staining,
chromogens were switched in some double
labeling studies, and more than one section
of the same block was stained using the
same antibody. For CD3/CD8 double-
label IHC, the primary antibodies were
incubated simultaneously, while the sec-
ondary antibody steps were performed
sequentially.
Quantitative  analysis  and  statis-
tics.  Sections with single label immun-
ostaining for CD45 isoforms (RA, RC, RB
and RO) were analyzed by counting the
total positive cells in the cerebral white
matter of ten 400×  random microscope
ﬁelds per case and averaging the number.
Only processes adjacent to evident nuclei
were considered cells and, in HIVE cases,
MGCs were counted as single cells. Cell
type-speciﬁc CD45RO+ cell counts were
also obtained as average numbers from six
200× ﬁelds. Cell types were distinguished
based on morphology and location:
parenchymal microglia (process-bearing),
perivascular macrophages (elongated or
round without processes) and parenchymal
or perivascular lymphocytes (small and
round and intensely CD45+). CD3 and
CD8 cells were counted in six 400× micro-
scope ﬁelds and expressed as average per-
Table 1. Antibodies and immunohistochemical methods adopted in this study.
Antigen Antibody clone/isotype Source Dilution Methods
CD45 LCA (PD7/26 + 2B11), IgG1 DAKO (Carpinteria, Calif.) 1:100 TSA*
CD45RA HI100, IgG2b Pharmingen (San Diego, Calif.) 1:100 TSA
CD45RB MT4, IgG1 Pharmingen 1:100 TSA
CD45RC MT2, IgG1 Biogenex (San Ramon, Calif.) 1:40 TSA
CD45RO UCHL-1, IgG2a DAKO 1:50 TSA
CD3 Polyclonal Cell Marque Corp (Austin, Tex.) 1:250 TSA
CD8 1A5, IgG1 Vector (Burlingame, Calif.) 1:40 ABC†
CD68 KP1, IgG1 DAKO 1:600 Two-step‡
VWF Polyclonal DAKO 1:400 ABC
*Tyramide signal ampliﬁcation. See Materials and methods for details. †Avidin–biotin complex without TSA. ‡Alkaline phosphatase-labeled secondary antibody methods without
TSA. Abbreviations: LCA = leukocyte common antigen; VWF = Von Willebrand Factor.258 Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al
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centage (CD8+/CD3+  divided by total
CD3) from four cases.
Graphs were generated using GraphPad
Prism 4.0 and are presented in a box plot
format where the median is indicated by
a central line and the range is shown by
the whiskers. The box displays the 25–75
percentiles. Statistical analyses comparing
the cell counts among the three groups
(HIV−, HIV+ and HIVE) were performed
by one-way ANOVA followed by Bonfer-
roni pairwise comparison. If no differences
Figure 1. CD45 isoform expression in HIV encephalitis (HIVE) and control brains. Sections of the control and HIVE brains are immunostained with antibodies
against CD45RA, RB, RC or RO as described in the Materials and methods. Results of the two non-HIVE controls groups (HIV− and HIV+) are similar (also see
Figures 2 and 3E), but only HIV+ are shown here. Panels A–D show HIV-seropositive brains stained with αRA, αRB, αRO and αCD68. Panels E–H show serial
sections of an HIVE brain depicting a microglial nodule immunostained for CD45 isoforms and CD68. The αRA- and αRC-reactive cells are mainly limited to
leukocytes within the bloodstream with rare perivascular and/or parenchymal positive cells noted in both non-HIVE and HIVE brains (A, E and I, also see
Figure 2). αRB-reactive cells are abundant in all brains and they include ramiﬁed microglial cells in HIV− (see Figure 5A) and HIV+ (B), as well as activated
microglial cells within and outside the microglial nodules in HIVE (F and J). Multinucleated giant cells (MGCs) are also RB+ (asterisk, M). Panel J demonstrates
a high power image of αRB-reactive perineuronal microglia in the gray matter (arrowheads). αRO reactivity is detected in inﬁltrating lymphocytes, perivascular
macrophages and microglial cells in HIVE (G), including MGCs (asterisk, K). Some MGCs are RO− (asterisk: L). Control brains show more limited RO staining (C
and also see Figure 3E). Microglia and macrophages in non-HIVE and HIVE brains are positive for CD68, a marker of brain macrophages (D and H). An HIV+
section treated with normal mouse IgG2a is shown as a control (N). Sections are counterstained with hematoxylin. The scale bar represents 50 µm in A–H
and N, 100 µm in I and 20 µm in I inset and J–M.Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al 259
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were found, t-test was performed to com-
pare HIVE and non-HIVE (combined
HIV−  and HIV+) groups. P < 0.05  was
considered signiﬁcant, unless stated other-
wise. All statistics were performed using
GraphPad Prism.
RESULTS
Expression of CD45 isoforms in HIVE
and  controls  (Figure 1).  Using a pan-
CD45-reactive antibody we have previ-
ously shown that CD45 is expressed in
normal microglia and is upregulated in
HIVE (7). In this study, CD45 isoform
expression was analyzed using extracellular
exon-speciﬁc antibodies in control (HIV−
and HIV+, HIV+  shown in A–D) and
HIVE (E–N) brains with respect to several
cell types (Figure 1). Results with single-
label IHC are illustrated in Figure  1.
αCD45RA and αCD45RC staining was
limited to lymphocytes mostly within the
lumina (or lumens) of the vessels. A few
RA- or RC-positive lymphocytes were also
present in the perivascular space and in the
parenchyma of HIVE and control brains
(Figure 1A,E,I). αCD45RB showed stain-
ing of ramiﬁed microglia in control brains
and staining of inﬁltrating leukocytes and
microglia including MGCs in HIVE
(Figure  1B,F,J,M, also see Figure  5A for
HIV−). αCD45RO staining was variable
in microglia in control brains (Figure 1C,
also see Figure  3F for HIV−), but was
detected in lymphocytes, macrophages
and microglia, including MGCs in HIVE
(Figure 1G,K,L, also see Figure 3G). Con-
trol staining for macrophage/microglial
(D,H) distribution and with an antibody
isotype (N) is shown. The αRB reactivity
in the absence of αRA or αRC reactivity
indicates that the αRB-reactive isoform is
B and not ABC, AB or BC (45). Therefore,
of the ﬁve CD45 isoforms, those expressed
in microglia, macrophages and the vast
majority of lymphocytes in HIVE (and
controls) are CD45RB and CD45RO.
Quantitative analysis of CD45 isoform
expression  (Figure 2).  The  αRA,  αRC,
αRB and αRO-reactive cell counts in the
three patient groups (HIV−, HIV+  and
HIVE) are shown in Figure 2. αCD45RA-
and  αRC-reactive cells were rare
averaging—one cell per 400× ﬁeld in HIVE
and even fewer in control brains
(Figure 2A,B). Neither RA nor RC counts
were signiﬁcantly different among groups
(NS = not signiﬁcant). As RB+ and RO+
cells included heterogeneous cell popula-
tions, they were further divided into paren-
chymal (Par) and perivascular (PV)
populations and the numbers were com-
pared. Because of constitutive expression in
normal microglia, CD45RB parenchymal
counts were uniformly high in all three
groups (P > 0.05), averaging ∼50 per 400×
ﬁeld (Figure 2C). By contrast, perivascular
RB counts were signiﬁcantly elevated in
HIVE compared with HIV− (P < 0.001) or
HIV+ (P < 0.01). The total RB counts in
HIVE, but showed an upward trend, were
not signiﬁcantly elevated. CD45RO counts
were also determined in 400× ﬁeld for com-
parison. Overall, RO counts were consid-
erably lower than RB counts in all patient
groups (Figure 2D). When RO counts were
compared between groups, the parenchy-
mal (but not perivascular) RO counts in
HIVE were signiﬁcant elevated compared
with the HIV+ group. The total RO counts
were  also signiﬁcantly elevated in HIVE
compared with HIV+ (also see below).
Cell type-speciﬁc quantitation of
CD45RO  expression  (Figure 3).  As
CD45RO expression alone was signiﬁ-
cantly elevated in HIVE, we further ana-
lyzed RO expression on different cell types
in HIVE and control brains. RO+  cells
were  enumerated in 200×  microscopic
ﬁeld according to their morphology and
location. Examples are shown in
Figure  3E,F: (i) perivascular lymphocytes
(arrowheads); (ii) parenchymal lympho-
cytes (arrows); (iii) perivascular macroph-
ages (mΦ); and (iv) parenchymal microglia
(m). While microglia are ramiﬁed, perivas-
cular macrophages are round or elongated
in shape. The identity of these cells is con-
ﬁrmed by double labeling for T cell and
macrophage markers (see Figures 5 and 6
below). The results show that the number
of CD45RO+ cells increased in HIVE in
Figure 2. Quantitative analysis of CD45 isoform expression in human brain. In single-stained sections,
average numbers of CD45RA, RB, RC and RO-reactive cells per 400× ﬁeld were calculated and compared
as described in Materials and methods. (A) CD45RA+ and (B) CD45RC cells were very rare relative to RB+
and RO+ cells, but showed a trend for elevation in HIVE. The numbers were not signiﬁcantly different
(NS) by ANOVA or t-test. (C) CD45RB and (D) CD45RO counts were obtained with respect to their location,
parenchymal (Par), perivascular (PV) or total (combined Par + PV). CD45RB and RO counts are higher
than RA or RC counts (see the differences in Y-axis scales in A though D) and CD45RB counts are higher
than RO counts. The numbers in the three groups (HIVE, HIV− and HIV+) were compared in each category
and showed that while perivascular CD45RB counts were signiﬁcantly elevated in HIVE compared with
either control group (P < 0.01 by ANOVA), no signiﬁcant increases in parenchymal or total RB counts
were  seen. By contrast, RO counts were signiﬁcantly elevated in HIVE (compared with HIV+  group
*P < 0.05 by ANOVA) in the parenchyma. The total RO counts were also signiﬁcantly elevated in HIVE
compared with HIV+ (*P < 0.05 by ANOVA).260 Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al
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all categories, except for perivascular lym-
phocytes (Figure  3A–D). Because signiﬁ-
cant inﬂammatory cell (macrophages and
lymphocytes) inﬁltration occurs only in
HIVE, the increase in CD45RO+ T cell
and macrophage number in HIVE repre-
sents the presence of these new cell inﬁl-
trates (Figure 3A–C). On the other hand,
the increase in microglial CD45RO in
HIVE represents that a larger proportion
of microglia are positive for CD45RO
(Figure  3D). The staining intensity in
RO+ microglia appears to have increased
in HIVE as well (see Figure  3E,F, for
example), but our analysis only reﬂected
the CD45+ cell numbers.
Relative CD45RB and RO expression
on different cell types based on immuno-
histochemical detection methods with
different sensitivity (Figure 4). Reports of
αCD45 labeling of microglia vary (1, 7,
13, 24, 33, 46, 56). We tested immunohis-
tochemical techniques with differing sensi-
tivity to determine whether microglial
CD45 immunoreactivity varies depending
on the technique and cell type. AR in the
form of boiling of the parafﬁn sections in
sodium citrate buffer is commonly used
to increase the antigen detection. TSA is
another method that increases the sensitiv-
ity of staining by up to two logs (21, 47).
We  have compared three conditions (no
treatment, AR alone, and AR plus TSA) for
detection of RB and RO. Examples from
an HIVE case are shown in Figure 4. Both
RB and RO stains are limited to lympho-
cytes without AR or TSA (Figure 4A,D).
With AR, lymphocyte staining is in-
tensiﬁed and some non-lymphocyte stain
becomes detectable, especially for RB
(Figure  4B,E). With AR plus TSA, lym-
phocyte staining is greatly intensiﬁed and
more microglia and macrophages become
detectable (Figure 4C,F). CD45RB stain-
ing intensity tends to be greater than
CD45RO staining, particularly on non-
lymphoid cells [compare top (RB) and bot-
tom (RO) panel], regardless of the HIV
status (not shown).
CD45RB and CD45RO in macrophages
and microglia (Figure 5). To  conﬁrm the
identity of CD45+  cells, we performed
double labeling with macrophage markers
(CD68) or T cell markers (CD3).
Figure  5A demonstrates overlapping of
CD68+  and CD45RB+  populations in
control HIV− brain conﬁrming that they
are microglia. Figure  5B demonstrates
CD68+/CD45RB+  cells in perivascular
and parenchymal locations (HIVE) signi-
fying macrophages and microglia. Double
labeling for CD45RO and CD45RB
showed that all CD45RO+ microglia were
also CD45RB+ (Figure 5C, HIVE). Many
of the CD45RO+ cells were also HIV-1
p24+ in HIVE (Figure 5D–H). Exceptions
were  lymphocytes that were CD45RO+
Figure 3. Quantitative analysis of CD45RO expression. CD45RO+ cells were counted at 200× based on cell
type (A–D). Examples of each cell type are shown in E (HIV−) and F [HIV encephalitis (HIVE)]. Arrows
indicate parenchymal lymphocytes; arrowheads, perivascular lymphocytes; m, microglia; and mΦ, mac-
rophages. A and B. No difference was noted in the RO+ perivascular T cell counts among groups, while
the RO+ parenchymal T cell count was signiﬁcantly elevated in HIVE compared with either control group
by ANOVA. C and D. The number of perivascular macrophages and parenchymal microglia were also
signiﬁcantly elevated in HIVE compared with none-HIVE (combined HIV−/HIV+,  t-test). The scale bar
represents 25 µm in E and 50 µm in F.Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al 261
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but p24−  (Figure  5D,E: small, round,
brown cells throughout). We ﬁnd most
MGCs to be p24+  and CD45RO+
(Figure 5F–H), though RO− MGCs were
also observed (Figure  5H, MGC to the
right). For instance, cell counting in one
case showed 83% of a total of 57 MGCs
to be CD45RO+/p24+  and 17%
CD45RO−/p24+.
Most lymphocytes in HIVE are CD8+ + + +
(Figure 6).  To  ascertain the identity of
CD45RO+ and CD45RB+ lymphocytes,
we stained the sections for CD3 (pan T-
cell) and CD8. Multiple attempts at CD4
staining did not produce reliable results.
Thus, we inferred CD4 expression from
CD3/CD8 double-labeled sections
(CD3+/CD8−). Double labeling showed
that CD45RO+  lymphocytes were also
CD3+  (Figure  6A) and CD45RB+
(Figure  6B). We compared the number
and distribution of CD8+  cells and
CD45RO+ lymphocytes in single-stained
serial sections. Low and high power views
of a microglial nodule (Figure 6C–E) dem-
onstrate that CD8+ and CD45RO+ cell
distributions overlap, suggesting that lym-
phocytes in HIVE are CD8+ T cells. The
lymphocytes (CD45RO+, CD8+) were in
close contact with p24+ MGCs, but they
themselves were p24−  (Figure 6F,  also
see J). Double staining revealed that the
majority of CD3+ cells were also CD8+
(Figure 6H,I). Quantitation in four HIVE
cases showed that 97.5% ± 1.0% (mean ±
SEM) of CD3+ cells were CD8+. CD3+/
CD8−  cells (presumably CD4+  T cells)
were  detected, but very rarely
(Figure  6H,I). Double labeling with an
endothelial speciﬁc antigen [(Von Wille-
brand Factor (VWF)] conﬁrmed the
parenchymal location of CD8 cells in
HIVE (Figure  6L). In control brains,
CD8+ cells were few and limited to the
perivascular region (Figure  6M). CD8+
cell counts were determined as average in
six 400×  ﬁelds and showed a signiﬁcant
increase in HIVE over combined control
groups (Figure 6K).
DISCUSSION
In this study, we demonstrate that the
predominant CD45 isoforms expressed in
HIVE and control brains are CD45RB and
CD45RO. Based on the reactivity to exon-
speciﬁc antibodies we determined that of
the four RB-containing isoforms (ABC,
AB, BC, B), the αRB-reactive isoform in
macrophages and microglia is CD45RB
and not ABC, AB or BC. The predominant
αRB-reactive isoform in CNS-inﬁltrating
lymphocytes is also RB, since RA- or RC-
expressing cells were extremely rare.
CD45RO was also detected in all three cell
types. The pattern of CD45 isoform
expression in microglia in human CNS is
similar to that in vitro. Cultured human
microglia contain abundant CD45RB, and
a low level of CD45RO, but no αRA- or
αRC-reactive isoforms (25). The robust
expression of CD45RB in microglia in nor-
mal human brain supports the potential
usefulness of CD45RB as a marker of rest-
ing microglia, since the majority of widely
used markers identify activated cells (19,
36). In addition, CD45’s membrane
expression is particularly useful in delineat-
ing the relationship between microglia and
adjacent neural cell types, such as neurons
(see Figure 1J, for example).
Because of the constitutive expression of
CD45RB in normal microglia, quantita-
tive analysis did not reveal that CD45RB
Figure 4. Comparison of immunohistochemistry (IHC) methods: the effect of antigen retrieval and tyramide signal ampliﬁcation (TSA) on CD45 detection. Six serial
sections of the same case were immunostained for CD45RB (top panel) and CD45RO (bottom panel) under three different conditions: no treatment (A and
D), antigen retrieval (AR) (B and E), and AR plus TSA (C and F). Without AR, CD45RB or CD45RO immunoreactivity is shown in lymphocytes only (arrows, A
and D). With AR, lymphocyte staining for RB (arrows in B) and RO (asterisk in E) is increased (RB > RO) and some microglial staining becomes detectable
(arrowheads in B). AR plus TSA further enhances RB staining in microglia (arrowheads in C) and lymphocytes (asterisk in C) and RO staining for all cells (microglia
indicated with arrowheads in F). The scale bar represents 50 µm.262 Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al
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counts were signiﬁcantly increased in
HIVE. Unlike CD45RB, the CD45RO
counts showed a signiﬁcant increase in
HIVE. When CD45RO counts were
analyzed according to the cell type, this
increase was due to RO+ T cells, macroph-
ages as well as microglia. While the expres-
sion of CD45RO in CNS-inﬁltrating T
cells is well known (55), its expression in
microglia and macrophages is less well
appreciated. We ﬁnd that highly sensitive
TSA ampliﬁcation was required for detec-
tion of microglial and macrophage
CD45RO. Unlike CD45RB, CD45RO
expression in control microglia (in both
HIV−  and HIV+  brains) was variable.
Although there is a high overlap between
HIV-1 p24 expression and CD45RO reac-
tivity in macrophages and microglia, the
increase in CD45RO reactivity is unlikely
to be unique to HIVE. Indeed, CD45RO+
microglia have been found in Alzheimer’s
brains concentrated in senile plaques (1).
Initially created for immunoassays (3),
the TSA system utilizes catalyzed reporter
deposition technique that enhances immu-
nolabeling by 10- to 100-fold (21, 39).
Previously, staining for CD45 antigen has
been performed without the TSA method
(1, 13, 33, 36, 38, 44). We observe that
TSA was invaluable in detecting CD45RO
on both macrophages and microglia, while
detection of CD45RO on T cells did not
require TSA. These results suggest that
CD45RO expression in T cells must be at
least one to two orders of magnitude
higher than that in macrophages or micro-
glia. Similar results are found in FACS
analysis studies of ex vivo  cells which
Figure 5. Analysis of CD45-positive microglia, macrophages and multinucleated giant cells (MGCs). Double-label studies with macrophage antigens. Note the
color of the antibody label matches the color of the chromogen. All panels show HIVE brain except A (HIV− control). Microglia in normal brain are double
positive for CD45RB/CD68 (A). In HIVE, perivascular macrophages and microglia are double positive for CD45RB/CD68 (B). CD68 (brown) is intracellular
(arrowheads) while CD45 is on the cell surface (insets, A and B). Microglia double positive for CD45RB and CD45RO in HIVE (C, high power view in inset).
Intracellular HIV-1 p24 stain marks productively infected cells including MGCs (D–H). Low power showing CD45RO+/p24+ microglia in diffuse (D) and focal
(E) distribution. Note that lymphocytes are CD45RO+ but p24−. A high power view of CD45RO+/p24+ perivascular macrophages (F). Most p24+ MGCs are
strongly CD45RO+ (G, H). Scale bar represent 300 µm (A–E), 30 µm (F and H), 75 µm (G) and 60 µm (insets of A–C).Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al 263
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showed higher levels of CD45 in lympho-
cytes than in monocytes or microglia (9).
In our analysis of HIVE sections, we ﬁnd
the majority of strongly CD45+ inﬂamma-
tory cells to be T cells rather than mono-
cytes or macrophages. These results
contrast with those of others who found
monocytes and macrophages to be the pre-
dominant cells with high CD45 expression
(13, 18). Some of the strongly CD45+ cells
in these studies appear to have been misi-
dentiﬁed as macrophages, as they have the
typical morphology of lymphocytes. We
ﬁnd it difﬁcult to deﬁnitively identify
CD45+  monocytes and macrophages in
HIVE without simultaneously labeling for
T cell markers.
We observe that the number of T cells
inﬁltrating HIVE brain can be very high.
Surprisingly, a substantial number of T
cells were within the brain parenchyma
often associated with HIV-1 infected cells
and/or microglial nodules. We also found
the majority of T cells in HIVE to be
CD8+, in agreement with previous reports
(26, 34). Similar ﬁndings were reported for
simian immunodeﬁciency virus encephali-
tis (26, 32) and may in part reﬂect the
general CD4+ T cell deﬁciency in AIDS.
However,  CD8+  inﬁltrates devoid of
CD4+  T cells have been reported in
immune-restored post-HAART individu-
als (34). The predominance of CD8+ cells
found in this and other studies predicts
that T cells are unlikely to be reservoirs of
HIV-1 within the CNS (44, 55).
We have demonstrated that, despite the
generally low level of microglial CD45RO,
triggering this molecule with an antibody
(UCHL-1) in vitro has a profound effect
in human microglia. αCD45RO virtually
completely suppressed GM-CSF-induced
microglial proliferation (48) and potently
suppressed HIV-1 replication (25). Inter-
Figure 6. Characterization of T cell inﬁltrates in HIV
encephalitis (HIVE). Immunolabeled serial sections
of three different microglial nodules are dis-
played. The chromogen marking the antibody is
indicated by the color of the text. The ﬁrst set
shows CD45RO+/CD3+ (A) or CD45RO+/RB+ (B)
small round lymphocytes. Double-labeled cells
appear darker than single-labeled cells (see
insets). CD8+ cells are observed in microglial nod-
ules, but are also scattered throughout the paren-
chyma (C–K). Serial sections of two microglial
nodules indicate that the number and distribu-
tion of CD8+ and CD45RO+ cells correspond (C–
F). CD8+ cells are seen adjacent to p24+ cells (F)
and unstained MGCs (arrows in J). To verify the
identity of the T lymphocytes, double labeling for
CD3 and CD8 was performed and the majority are
CD3/CD8 double labeled (H, I). CD3+/CD8− cells
(brown, arrowheads, insets) are noted but rare.
The parenchymal position of most CD8+ cells in
HIVE is evident in sections labeled for an endot-
helial antigen, Von Willebrand Factor (VWF, L).
CD8+  cells in control brains are limited in the
perivascular distribution (M). CD8+ cell counts are
increased in HIVE compared with combined con-
trol groups by t-test.  The scale bar represents
120 µm (A, B, E, F, L), 240 µm (C and D), 60 µm (G–
J and M) and 50 µm (all insets).264 Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al
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estingly, αCD45RB antibodies in human
microglia did not induce any activity (25,
48), whereas in the mouse, α-CD45RB
suppressed microglial activation and
induced tolerance to transplantation rejec-
tions (49, 50, 53). Given the robust expres-
sion of CD45RB in human microglia,
these results reﬂect the effectiveness of
individual antibodies rather than species-
dependent differences in the expression
of CD45 isoforms. The expression of
CD45RB in human cells suggests that this
CD45 isoform may also be targeted with
an effective antibody.
Our study showing CD45 expression in
microglia may have clinical applications.
CD45 has been shown to be functionally
important in murine models of Alzheimer’s
disease (49), and microglial CD45 may be
a potential therapeutic target in inﬂamma-
tory CNS diseases, as has been proposed
for systemic immunological and neoplastic
diseases (23). Natural CD45 ligands have
not been identiﬁed despite extensive
searches (16) but CD45 tyrosine phos-
phatase activity can be modulated by anti-
bodies, RNAi or gene deletion (22, 23, 40,
48). Inhibition of CD45 expression by the
latter two methods have resulted in an
activated cell phenotype, indicating that
CD45 normally functions to maintain the
suppressed cell phenotype (22, 49). There-
fore, an antibody approach remains an
ideal option to target CD45 to suppress
cell activity and inﬂammation. Our work
suggests a therapeutic potential for
αCD45RO for AIDS dementia and possi-
bly for other inﬂammatory and neurode-
generative disorders in which suppression
of microglial activation is desirable.
ACKNOWLEDGMENTS
The authors thank the Manhattan
HIV brain bank (R24MH59724) of the
National NeuroAIDS Tissue Consortium
for autopsy tissues, and Drs. Teresa P.
DiLorenzo and Howard Ratech for helpful
discussions. This study was supported by
NIH RO1 MH55477 and the Einstein
CFAR AI051519. MCN was supported by
the NIH Training Grant NS 07098.
REFERENCES
1. Akiyama H,  Ikeda K,  Katoh M,  McGeer EG,
McGeer PL (1994) Expression of MRP14, 27E10,
interferon-alpha and leukocyte common antigen
by reactive microglia in postmortem human brain
tissue. J Neuroimmunol 50:195–201.
2. Altin JG, Sloan EK (1997) The role of CD45 and
CD45-associated molecules in T cell activation.
Immunol Cell Biol 75:430–445.
3. Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ
(1989) Catalyzed reporter deposition, a novel
method of signal ampliﬁcation. Application to
immunoassays. J Immunol Methods 125:279–285.
4. Byth KF, Conroy LA, Howlett S, Smith AJ, May J,
Alexander DR, Holmes N (1996) CD45-null trans-
genic mice reveal a positive regulatory role for
CD45 in early thymocyte development, in the
selection of CD4+CD8+  thymocytes, and B cell
maturation. J Exp Med 183:1707–1718.
5. Cale CM, Klein NJ, Novelli V, Veys P, Jones AM,
Morgan G (1997) Severe combined immunodeﬁ-
ciency with abnormalities in expression of the
common leucocyte antigen, CD45. Arch Dis Child
76:163–164.
6. Cosenza M,  Zhao M-L,  Shankar SL,  Shaﬁt-
Zagardo B, Lee SC (2002) Upregulation of MAP2e-
expressing oligodendrocytes in the white matter
of patients with HIV-1encephalitis. Neuropathol
Appl Neurobiol 28:480–488.
7. Cosenza M,  Zhao M-L,  Si Q,  Lee SC (2002)
Human brain parenchymal microglia express
CD14 and CD45 and are productively infected by
HIV-1 in HIV-1 encephalitis. Brain Pathol 12:442–
455.
8. Deszo EL, Brake DK, Cengel KA, Kelley KW, Fre-
und GG (2001) CD45 negatively regulates mono-
cytic cell differentiation by inhibiting phorbol
12-myristate 13-acetate-dependent activation
and tyrosine phosphorylation of protein kinase
Cdelta. J Biol Chem 276:10212–10217.
9. Dick AD, Pell M, Brew BJ, Foulcher E, Sedgwick
JD (1997) Direct ex vivo ﬂow cytometric analysis
of human microglial cell CD4 expression: exami-
nation of central nervous system biopsy speci-
mens from HIV-seropositive patients and patients
with other neurological disease. AIDS  11:1699–
1708.
10. Dickson DW, Lee SC (1997) Microglia. In: Text-
book of Neuropathology. RL Davis, DM Robertson
(eds), pp. 165–205. Williams & Wilkins: Baltimore.
11. Dickson DW, Lee SC, Mattiace L, Yen S-H, Bros-
nan CF (1993) Microglia and cytokines in neuro-
logical disease, with special reference to AIDS and
Alzheimer’s disease. Glia 7:75–83.
12. D’Oro U, Ashwell JD (1999) Cutting edge: the
CD45 tyrosine phosphatase is an inhibitor of Lck
activity in thymocytes. J Immunol 162:1879–1883.
13. Fischer-Smith T, Croul S, Sverstiuk AE, Capini C,
L’Heureux D, Regulier EG, Richardson MW, Amini
S,  Morgello S,  Khalili K,  Rappaport J (2001) CNS
invasion by CD14+/CD16+  peripheral blood-
derived monocytes in HIV dementia: perivascular
accumulation and reservoir of HIV infection. J
Neurovirol 7:528–541.
14. Genis P,  Jett M,  Berton EW,  Boyle T,  Gelbard
HA,  Dzenko K,  Keane RW,  Resnick L,  Mizrachi Y,
Volsky DJ,  Epstein LG,  Gendelman HE (1992)
Cytokines and arachidonic acid metabolites pro-
duced during human immunodeﬁciency virus-
infected macrophage-astroglia interactions:
implications for the neuropathogenesis of HIV
disease. J Exp Med 176:1703–1718.
15. Gonzalez-Scarano F,  Baltuch G (1999) Micro-
glia as mediators of inﬂammatory and degenera-
tive diseases. Annu Rev Neurosci 22:219–240.
16. Hermiston ML, Xu Z, Weiss A (2003) CD45: a
critical regulator of signaling thresholds in
immune cells. Annu Rev Immunol 21:107–137.
17. Hickey WF,  Vass K,  Lassmann H (1992) Bone
marrow-derived elements in the central nervous
system: an immunohistochemical and ultrastruc-
tural survey of rat chimeras. J Neuropathol Exp
Neurol 51:246–256.
18. Hickey WF,  Williams KC,  Corey S,  Kim W-K
(2005) Mononuclear phagocyte heterogeneity
and the blood-brain barrier: a model for HIV-1
neuropathogenesis. In: The Neurology of AIDS. HE
Gendelman, I Grant, IP Everall, SA Lipton, S Swin-
dells (eds), pp. 71–83. Oxford University Press:
New York.
19. Horikoshi Y,  Sasaki A,  Taguchi N,  Maeda M,
Tsukagoshi H, Sato K, Yamaguchi H (2003) Human
GLUT5 immunolabeling is useful for evaluating
microglial status in neuropathological study
using parafﬁn sections. Acta Neuropathol (Berl)
105:157–162.
20. Huntington ND,  Tarlinton DM (2004) CD45:
direct and indirect government of immune regu-
lation. Immunol Lett 94:167–174.
21. Hunyady B,  Krempels K,  Harta G,  Mezey E
(1996) Immunohistochemical signal ampliﬁcation
by catalyzed reporter deposition and its applica-
tion in double immunostaining. J Histochem
Cytochem 44:1353–1362.
22. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky
A,  Cheng M,  Welstead G,  Grifﬁths E,  Krawczyk C,
Richardson CD,  Aitken K,  Iscove N,  Koretzky G,
Johnson P,  Liu P,  Rothstein DM,  Penninger JM
(2001) CD45 is a JAK phosphatase and negatively
regulates cytokine receptor signalling. Nature
409:349–354.
23. Irie-Sasaki J,  Sasaki T,  Penninger JM (2003)
CD45 regulated signaling pathways. Curr Top Med
Chem 3:783–796.
24. Johnston JB, Silva C, Gonzalez G, Holden J, War-
ren KG, Metz LM, Power C (2001) Diminished ade-
nosine A1 receptor expression on macrophages
in brain and blood of patients with multiple scle-
rosis. Ann Neurol 49:650–658.
25. Kim MO, Suh HS, Si Q, Terman BI, Lee SC (2006)
Anti-CD45RO suppresses HIV-1 replication in
microglia: role of Hck tyrosine kinase and implica-
tions for AIDS dementia. J Virol 80:62–72.
26. Kim WK, Corey S, Chesney G, Knight H, Klumpp
S,  Wuthrich C,  Letvin N,  Koralnik I,  Lackner A,
Veasey R,  Williams K (2004) Identiﬁcation of T
lymphocytes in simian immunodeﬁciency virus
encephalitis: distribution of CD8+ T cells in asso-
ciation with central nervous system vessels and
virus. J Neurovirol 10:315–325.
27. Kreutzberg GW (1996) Microglia: a sensor for
pathological events in the CNS. Trends Neurosci
19:312–318.
28. Kung C, Pingel JT, Heikinheimo M, Klemola T,
Varkila K, Yoo LI, Vuopala K, Poyhonen M, Uhari M,
Rogers M, Speck SH, Chatila T, Thomas ML (2000)
Mutations in the tyrosine phosphatase CD45Microglia Express CD45RB and CD45RO—Cosenza-Nashat et al 265
© 2006 The Authors
Journal Compilation © 2006 International Society of Neuropathology • Brain Pathology
gene in a child with severe combined immunode-
ﬁciency disease. Nat Med 6:343–345.
29. Lawson LJ, Perry VH, Gordon S (1992) Turnover
of resident microglia in the normal adult mouse
brain. Neuroscience 48:405–415.
30. Licastro  F, Mallory  M, Hansen  LA, Masliah
E (1998) Increased levels of alpha-1-
antichymotrypsin in brains of patients with Alzhe-
imer’s disease correlate with activated astrocytes
and are affected by APOE 4 genotype. J Neuroim-
munol 88:105–110.
31. McNeill L, Cassady RL, Sarkardei S, Cooper JC,
Morgan G, Alexander DR (2004) CD45 isoforms in
T cell signalling and development. Immunol Lett
92:125–134.
32. Marcondes MC,  Burudi EM,  Huitron-Resendiz
S, Sanchez-Alavez M, Watry D, Zandonatti M, Hen-
riksen SJ, Fox HS (2001) Highly activated CD8(+) T
cells in the brain correlate with early central ner-
vous system dysfunction in simian immunodeﬁ-
ciency virus infection. J Immunol 167:5429–5438.
33. Masliah E,  Mallory M,  Hansen L,  Alford M,
Albright T, Terry R, Shapiro P, Sundsmo M, Saitoh
T (1991) Immunoreactivity of CD45, a protein
phosphotyrosine phosphatase, in Alzheimer’s dis-
ease. Acta Neuropathol (Berl) 83:12–20.
34. Miller RF, Isaacson PG, Hall-Craggs M, Lucas S,
Gray F,  Scaravilli F,  An SF (2004) Cerebral CD8+
lymphocytosis in HIV-1 infected patients with
immune restoration induced by HAART. Acta Neu-
ropathol (Berl) 108:17–23.
35. Mitchell GB, Khandaker MH, Rahimpour R, Xu
L, Lazarovits AI, Pickering JG, Suria H, Madrenas J,
Pomerantz DK,  Feldman RD,  Kelvin DJ (1999)
CD45 modulation of CXCR1 and CXCR2 in human
polymorphonuclear leukocytes. Eur J Immunol
29:1467–1476.
36. Mittelbronn M, Dietz K, Schluesener HJ, Mey-
ermann R (2001) Local distribution of microglia in
the normal adult human central nervous system
differs by up to one order of magnitude. Acta Neu-
ropathol (Berl) 101:249–255.
37. Morgello S, Gelman BB, Kozlowski PB, Vinters
HV,  Masliah E,  Cornford M,  Cavert W,  Marra C,
Grant I, Singer EJ (2001) The National NeuroAIDS
Tissue Consortium: a new paradigm in brain
banking with an emphasis on infectious disease.
Neuropathol Appl Neurobiol 27:326–335.
38. Morner A, Thomas JA, Bjorling E, Munson PJ,
Lucas SB,  McKnight A (2003) Productive HIV-2
infection in the brain is restricted to macroph-
ages/microglia. AIDS 17:1451–1455.
39. Ness JM, Akhtar RS, Latham CB, Roth KA (2003)
Combined tyramide signal ampliﬁcation and
quantum dots for sensitive and photostable
immunoﬂuorescence detection. J Histochem
Cytochem 51:981–987.
40. Oliveira DM, Goodell MA (2003) Transient RNA
interference in hematopoietic progenitors with
functional consequences. Genesis 36:203–208.
41. Penninger JM, Irie-Sasaki J, Sasaki T, Oliveira-
dos-Santos AJ (2001) CD45: new jobs for an old
acquaintance. Nat Immunol 2:389–396.
42. Perry VH, Gordon S (1988) Macrophages and
microglia in the nervous system. Trends Neurosci
11:273–277.
43. Persidsky Y, Zheng J, Miller D, Gendelman HE
(2000) Mononuclear phagocytes mediate blood-
brain barrier compromise and neuronal injury
during HIV-1-associated dementia. J Leukoc Biol
68:413–422.
44. Petito CK,  Adkins B,  McCarthy M,  Roberts B,
Khamis I (2003) CD4+ and CD8+ cells accumulate
in the brains of acquired immunodeﬁciency syn-
drome patients with human immunodeﬁciency
virus encephalitis. J Neurovirol 9:36–44.
45. Schwinzer R (1989) Cluster report: cD45/
CD45R. In: Leucocyte Typing IV: White Cell Differen-
tiation Antigens.  W Knapp, B Dorken, P Rieber, R
Schmidt, WR Gilks (eds), pp. 628–634. Oxford Uni-
versity Press: Oxford.
46. Sedgwick JD,  Ford AL,  Foulcher E,  Airriess R
(1998) Central nervous system microglial cell acti-
vation and proliferation follows direct interaction
with tissue-inﬁltrating T cell blasts. J Immunol
160:5320–5330.
47. Shi SR,  Cote RJ,  Taylor CR (2001) Antigen
retrieval techniques: current perspectives. J His-
tochem Cytochem 49:931–937.
48. Suh HS,  Kim MO,  Lee SC (2005) Inhibition of
GM-CSF signaling and microglial proliferation by
anti-CD45RO: role of Hck tyrosine kinase and
PI3K/Akt. J Immunol 174:2712–2719.
49. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford
F,  Mullan M (2000) CD45 opposes beta-amyloid
peptide-induced microglial activation via inhibi-
tion of p44/42 mitogen-activated protein kinase.
J Neurosci 20:7587–7594.
50. Tan J, Town T, Mullan M (2000) CD45 inhibits
CD40L-induced microglial activation via negative
regulation of the Src/p44/42 MAPK pathway. J Biol
Chem 275:37224–37231.
51. Tchilian EZ,  Wallace DL,  Wells RS,  Flower DR,
Morgan G,  Beverley PC (2001) A deletion in the
gene encoding the CD45 antigen in a patient with
SCID. J Immunol 166:1308–1313.
52. Thomas ML (1989) The leukocyte common
antigen family. Annu Rev Immunol 7:339–369.
53. Townsend KP, Vendrame M, Ehrhart J, Faza B,
Zeng J, Town T, Tan J (2004) CD45 isoform RB as a
molecular target to oppose lipopolysaccharide-
induced microglial activation in mice. Neurosci
Lett 362:26–30.
54. Trowbridge IS,  Thomas ML (1994) CD45: an
emerging role as a protein tyrosine phosphatase
required for lymphocyte activation and develop-
ment. Annu Rev Immunol 12:85–116.
55. Weidenheim K, Epshteyn I, Lyman WD (1993)
Immunocytochemical identiﬁcation of T-cells in
HIV-1 encephalitis: implications for pathogenesis
of CNS disease. Mod Pathol 6:167–174.
56. Williams KC, Corey S, Westmoreland SV, Pauley
D,  Knight H,  deBakker C,  Alvarez X,  Lackner AA
(2001) Perivascular macrophages are the primary
cell type productively infected by simian immun-
odeﬁciency virus in the brains of macaques: impli-
cations for the neuropathogenesis of AIDS. J Exp
Med 193:905–915.
57. Yu C, Yu HS, Sun KH, Hsieh SC, Tsai CY (2002)
Anti-CD45 isoform antibodies enhance phagocy-
tosis and gene expression of IL-8 and TNF-alpha
in human neutrophils by differential suppression
on protein tyrosine phosphorylation and p56lck
tyrosine kinase. Clin Exp Immunol 129:78–85.
58. Zhao ML, Si Q, Lee SC (2004) IL-16 expression
in lymphocytes and microglia in HIV-1 encephali-
tis. Neuropathol Appl Neurobiol 30:233–242.